FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/01/061994 [Registered on: 29/01/2024] Trial Registered Prospectively
Last Modified On: 07/11/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Acute Normovolemic Haemodilution. An Intraoperative blood conservation strategy]  
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Scientific testing of a method called Acute Normovolemic Haemodilution to save blood during surgery for major urological cancer 
Scientific Title of Study   Acute Normovolemic Haemodilution in Urological malignancies: A randomized control study at a tertiary cancer center in Northern India 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Revathy Nair K 
Designation  Assistant Professor 
Affiliation  Mahamana Pandit Madan mohan Malaviya Cancer Centre, Varanasi 
Address  Department of Transfusion Medicine, Mahamana Pandit Madan mohan Malaviya Cancer Centre, Sundarbagiya,BHU campus, Sundarpur, Varanasi

Varanasi
UTTAR PRADESH
221005
India 
Phone  8113847901  
Fax    
Email  revathy@mpmmcc.tmc.gov.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Revathy Nair K 
Designation  Assistant Professor 
Affiliation  Mahamana Pandit Madan mohan Malaviya Cancer Centre, Varanasi 
Address  Department of Transfusion Medicine, Mahamana Pandit Madan mohan Malaviya Cancer Centre, Sundarbagiya,BHU campus, Sundarpur, Varanasi


UTTAR PRADESH
221005
India 
Phone  8113847901  
Fax    
Email  revathy@mpmmcc.tmc.gov.in  
 
Details of Contact Person
Public Query
 
Name  Dr Revathy Nair K 
Designation  Assistant Professor 
Affiliation  Mahamana Pandit Madan mohan Malaviya Cancer Centre, Varanasi 
Address  Department of Transfusion Medicine, Mahamana Pandit Madan mohan Malaviya Cancer Centre, Sundarbagiya,BHU campus, Sundarpur, Varanasi


UTTAR PRADESH
221005
India 
Phone  8113847901  
Fax    
Email  revathy@mpmmcc.tmc.gov.in  
 
Source of Monetary or Material Support  
Mahamana Pandit Madan mohan Malaviya Cancer Centre, Varanasi 
 
Primary Sponsor  
Name  Mahamana Pandit Madan mohan Malaviya Cancer Centre 
Address  Sundarbagiya, BHU campus, Sundarpur, Varanasi, Uttar Pradesh 221005 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Revathy Nair K  Mahamana Pandit Madan mohan Malaviya Cancer Centre  Department of Transfusion Medicine, Department of Anesthesiology, Department of Surgical Oncology
Varanasi
UTTAR PRADESH 
8113847901

revathy@mpmmcc.tmc.gov.in 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 4  
Name of Committee  Approval Status 
Institutional Ethics Committee, MPMMCC  Approved 
Institutional Ethics Committee, MPMMCC  Approved 
Institutional Ethics Committee, MPMMCC  Approved 
Institutional Ethics Committee, MPMMCC  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: O||Medical and Surgical,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Acute Normovolemic Haemodilution  The patients randomized to the intervention arm will receive autologous blood intraoperatively whenever there is an indication for transfusion. The blood collection of the patient will be performed after the induction of anesthesia just before commencement of the surgery. The volume of blood to be collected will be calculated as per the standard formula using EBV estimated blood volume, the initial and final Haemoglobin of the patient. The final haemoglobin of the patient will be fixed as 10g per dL. The blood will be collected into 350 ml blood bags sterile connected with 3 way cannula. During blood collection, the patient will be infused crystalloids in the ratio 1 is to 1 ie 1 ml crystalloid for every 1ml of blood collected to maintain normovolemia. The blood units collected will be labelled as per the order of collection. They will be labelled with the patient’s identifiers, a special instruction NOT to take them outside the Operation room and the expiry time of the blood unit. The autologous blood units collected will have to be transfused within 6 hours of collection within the OR. They can be stored at room temperature till then to retain the platelet activity. The blood will be transfused back to the patient within the OR even if there were no instances of maximum blood loss. 
Comparator Agent  Nil  The patients randomized to the control arm will receive allogeneic blood intraoperatively when indicated 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  Consenting patients of Surgical Urology posted for Radical cystecomy, resection of large masses with or without Inferior vena cava involvement, open radical prostatectomy, retroperitoneal lymph node dissection, partial nephrectomy, nephroureterectomy. The presurgical Hb of the patient must be within 12 to 16.5gper dL 
 
ExclusionCriteria 
Details  Non consenting patients, Active or history of coronary artery disease, cerebrovascular accident, chronic obstructive pulmonary disorder, renal dysfunction, liver dysfunction, abnormal coagulation parameters, active infection, Hb more than 16.5 and less than 12gperdL, history of allogeneic blood transfusion within 3 months of surgery, emergency surgeries and reexploration surgeries  
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Not Applicable 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Number of allogeneic blood transfusions performed intraoperatively  From the beginning of the surgery till the end of the surgery 
 
Secondary Outcome  
Outcome  TimePoints 
Morbidity and mortality in the form of Post operative complications assessed by Clavien Dindo classification  Upto 30 days following the surgery 
Expenses incurred during the hospital stay  Upto 30 days after the surgery 
Length of hospital stay  At the end of the hospital stay 
 
Target Sample Size   Total Sample Size="178"
Sample Size from India="178" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   01/02/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details
Modification(s)  
N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary
Modification(s)  

Background

Acute Normovolemic Hemodilution (ANH) is one of the blood conservation strategies wherein the patient’s whole blood is removed in a controlled manner immediately prior to surgery simultaneously maintaining the intravascular volume by administration of intravenous fluids. This reduces the patient’s intraoperative hematocrit thereby reducing the surgical red cell loss. The autologous blood collected is transfused to the patient at the end of the surgery or after the step of maximal blood loss [1]. Utility of ANH in oncology patients is not widely reported in India and hence, this study has been proposed anticipating the reduction in need for allogeneic blood and the expenditures incurred.

 Aims and Objectives

The Aim of the study is to evaluate Acute Normovolemic Hemodilution (ANH) in the setting of Urological malignancies.

The Objectives of the study are to

a. To determine if Acute Normovolemic Hemodilution (ANH) would decrease the allogeneic blood

requirement in Urological malignancies. (The null hypothesis is that ANH does not lead to reduction in allogeneic blood requirement)

b. To estimate the differences in expenses by avoiding allogeneic transfusions

c. To determine if ANH leads to reduction in morbid events and length of hospital stay. (The null hypothesis is that there is no reduction in morbid events and length of hospital stay with ANH)

 Subjects and Methods

The participants will be selected from the Elective surgical OT list published on the previous day of the surgery. They will be screened for inclusion and exclusion criteria based on the clinical and laboratory reports available on EMR. These patients will be explained the study in detail. They will be given a period of 10 to 12 hours for giving consent. The consenting participants will be randomized into either test or control arms by Simple randomization.

The participants in the standard arm will receive allogeneic blood transfusions when indicated intra and post operatively which is the usual institutional practice.

The participants randomized into the test arm will receive autologous blood when indicated intra operatively. If blood requirement arises post operatively, or if the intraoperative blood demand surpasses the autologous units, they will be transfused allogeneic blood. The autologous blood units will be collected after the induction of anesthesia under controlled conditions. The amount of whole blood to be removed will be calculated as per the formula:

V= EBV (H – Hf)/Hav

where V is the volume of blood collected preoperatively, H is the patient’s initial Hb, Hf is the patient’s final Hb after ANH. Hf will be fixed as 10g/dL for all the patients

Hav is the average of H and Hf

EBV-Estimated Blood Volume of the patient

EBV of the patient= Ideal body weight of patient x Blood volume (ml/Kg body weight) {Gilcher’s rule} [2]

Ideal body weight is computed in men as 50 + (0.91 × [height in centimeters - 152.4]) and in women as 45.5 + (0.91 × [height in centimeters - 152.4]). Blood volume (ml/kg) will be decided based on Gilcher’s rule.

Blood collection will be performed by a Co-investigator after induction of anesthesia, immediately before the commencement of the surgery. The target Hb of the patient will be fixed as 10g/dL. Blood will be collected into 350 ml standard blood collection bags  sterile connected with a three way cannula. The bag will be gently mixed to aid in anticoagulation. The bag’s weight will be constantly monitored to collect the optimum volume of blood into each bag. The patient will be simultaneously infused with crystalloids in the ratio 1:1 ie; for every 1 ml of whole blood collected, 1ml of crystalloid solution will be infused. As soon as the bag has the desired volume, it will be disconnected and labeled with the following information:

a. Name of the patient

b. Case number

c. Volume of blood

d. Sequential number of collection

e. Time of the collection.

f. Advice to transfuse within 6 hours

g. Signature of the blood collector

Heart rate, blood pressure, electrocardiogram, Central Venous Pressure, End tidal CO2 and oxygen saturation will be constantly monitored throughout the hemodilution procedure. The bags will be stored at room temperature for a maximum of 6 hours. They will be transfused when indicated intraoperatively. At the end of 6 hours, if there was no point of maximum blood loss, the blood units will be transfused within the Operating Room. The blood units will never be taken out of the Operation Room.

 

The following variables will be documented for participants of both arms:

Patient name, Age, Gender, Diagnosis, Surgery planned, Number of allogeneic blood units transfused intra and post operatively, Indications for transfusions, Complications in the post operative phase- Will be documented in descriptive manner, Length of hospital stay, Costs incurred throughout the hospital stay

The following variables will be additionally documented for test arm participants: Body weight, Height, Ideal body weight, Initial Hemoglobin H, Final Hemoglobin Hf, Hemoglobin average (Hav), Hematocrit, Estimated blood volume, Volume to be collected intraoperatively (V), Volume actually collected intraoperatively, Total hemodilution time, Volume of crystalloids infused during hemodilution, Descriptions of complications during hemodilution

The number of allogeneic blood units transfused intraoperatively will be the Primary end point of the study. For the secondary endpoints, the patients will be followed up for 30 days post surgery for morbid events as per Clavien Dindo classification [3], length of hospital stay and the expenses incurred during hospital stay.

 Statistical analysis

For preliminary analysis, descriptive statistics will be calculated for both continuous and categorical variables. The continuous variables will be presented as the mean±standard deviation (SD) or Median (IQR) based on the normality of the data. The categorical variables will be presented as numbers (percentages). Normality of the data will be assessed using Shapiro Wilk Test. A level of significance of 0.05 (= α) and 80% power of the study will be used for analysis. For the primary objective, to determine if Acute Normovolemic Hemodilution (ANH) would decrease the allogeneic blood requirement a two-sample t-test will be performed between the two arms. For comparing between categorical variables, chi-square test or fisher’s exact test will be performed. Any factors responsible for ANH will be determined using regression analysis. A p-value < 0.05 will be considered. All analysis will be performed using R Software (version 4.2.2).

 

The information in the study records will be kept confidential and the data will be housed in the Department of Transfusion Medicine. Principal Investigator and Co-Principal Investigator will have the rights to ’View’ and ’Edit’ the master chart. The Co-Investigators will have ’View’ rights. Data will be stored securely for a period of five years and will be made available only to persons conducting the study and to the regulatory authorities. The data will not be made available to another individual unless you specifically give permission in writing. No reference will be made in oral or written reports which could link you to the study. Result of the study will not be communicated to the participant unless deemed necessary

 

References 

1. Murray D. Acute normovolemic hemodilution. Eur Spine J. 2004 Oct;13 Suppl 1(Suppl 1):S72-5

2. Neyrinck MM, Vrielink H; Joint Task Force for Education and Certification. Calculations in apheresis. J Clin Apher. 2015 Feb;30(1):38-42.

3. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96


 
Close